Liquid biopsy technologies leverage DNA shed by normal and tumor cells to diagnose and monitor disease from a simple blood draw, allowing earlier detection of cancer or recurrence and providing genetic information to guide treatment. New priming agents developed by the Love and Bhatia labs, with collaborator Viktor Adalsteinsson, improve the tests’ sensitivity, information yield, and patient applicability. This work was supported in part by the Koch Institute Frontier Research Program via the Casey and Family Foundation, the Bridge Project, and the Marble Center for Cancer Nanomedicine.